Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
B2278
- Development stage
- Phase 2
- Lead developer
- Tasly Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramyocardial
01
Overview
B2278 is an investigational allogeneic cell therapy consisting of human umbilical cord-derived mesenchymal stem cells (HucMSCs), developed by Tasly Pharmaceutical Group. It is designed for the treatment of chronic heart failure (CHF) resulting from chronic ischemic cardiomyopathy (CICM). The therapy is administered via intramyocardial injection, often in conjunction with coronary artery bypass grafting (CABG) surgery. B2278 exerts its therapeutic effects through paracrine signaling, which promotes the polarization of macrophages toward a reparative (M2) phenotype, stimulates angiogenesis, and inhibits inflammatory responses. These mechanisms aim to facilitate myocardial repair and improve overall cardiac function in patients with end-stage ischemic heart disease.
- Other names
- Human umbilical cord mesenchymal stem cellsHucMSCsHuman umbilical cord mesenchymal stem cell injection
Beyond the preview
Go deeper on B2278.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on B2278.